Inqovi Prices, Coupons and Patient Assistance Programs
Inqovi (cedazuridine/decitabine) is a member of the antineoplastic combinations drug class and is commonly used for Myelodysplastic Syndrome.
The cost for Inqovi oral tablet (100 mg-35 mg) is around $8,539 for a supply of 5 tablets, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Inqovi is available as a brand name drug only, a generic version is not yet available. View generic Inqovi availability for more details.
Inqovi prices
Oral Tablet
Quantity | Per unit | Price |
---|---|---|
5 | $1,707.71 | $8,538.55 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Inqovi Coupons, Copay Cards and Rebates
Inqovi offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
Drugs.com Printable Discount Card
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Print Free Discount CardNote: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, CVS Pharmacy, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.
Inqovi Taiho Oncology Patient Support Co-pay Assistance Program
Eligible commercially insured patients may pay $0 per treatment cycle; for additional information contact the program at 844-824-4648.
- Applies to:
- Inqovi
- Number of uses:
- Per prescription until program expires
Form more information phone: 844-824-4648 or Visit website
Inqovi Medicare Part D Extra Help Subsidy
Patients who have Medicare Part D coverage may be eligible to apply for the Part D Extra Help Subsidy and once accepted to the program may receive reduced premiums and lower prescription costs; contact the program directly for questions or to sign-up.
- Applies to:
- Inqovi
- Number of uses:
- Per prescription until program expires
Form more information phone: 800-772-1213 or Visit website
Patient Assistance & Copay Programs for Inqovi
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: Patient Access Network Foundation (PAN)
Eligibility requirements:- *See Additional Information section below
- Between 400-500% of FPL
- FDA Approved Diagnosis - See Program Website for Details
- Must reside and receive treatment in US
- *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
- Inqovi (decitabine/cedazuridine) Tablet
More information please phone: 866-316-7263 Visit Website
Provider: Taiho Oncology Patient Support Program
Eligibility requirements:- Must be uninsured or underinsured
- Not disclosed
- FDA-approved diagnosis
- Must be residing in the US or a US territory, and under the care of a US physician
- Co-payment assistance, reimbursement support, patient support, and patient assistance programs are available for eligible patients.
- Inqovi (decitabine/cedazuridine) Tablet
More information please phone: 844-824-4648 Visit Website
More about Inqovi (cedazuridine / decitabine)
- Check interactions
- Compare alternatives
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antineoplastic combinations
- En español